Back to Search Start Over

Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer

Authors :
Heather H. Cheng
Alexandra O. Sokolova
Roman Gulati
Deborah Bowen
Sarah A. Knerr
Nola Klemfuss
Petros Grivas
Andrew C. Hsieh
John K. Lee
Michael T. Schweizer
Todd Yezefski
Alicia Zhou
Evan Y. Yu
Peter S. Nelson
Bruce Montgomery
Source :
JCO Precision Oncology.
Publication Year :
2023
Publisher :
American Society of Clinical Oncology (ASCO), 2023.

Abstract

PURPOSE Germline mutations in DNA repair genes are present in approximately 10% of men with metastatic prostate cancer (mPC), and guidelines recommend genetic germline testing. Notable barriers exist, including access to genetic counseling, insurance coverage, and out-of-pocket costs. The GENTleMEN study was designed to determine the feasibility of an Internet-based, patient-driven germline genetic testing approach for men with mPC. PATIENTS AND METHODS In this prospective cohort study, men with mPC provided informed consent via an Internet-based platform and completed a questionnaire including demographics and family cancer history. Supporting medical data were also collected. Genetic testing was performed using the Color Genomics 30-gene targeted panel of cancer predisposition genes on a mailed saliva sample. Men whose test results identified a germline pathogenic or likely pathogenic variant received results by phone or telehealth genetic counseling; other participants received results by email with an option for phone-based or telehealth genetic counseling. RESULTS As of August 18, 2021, 816 eligible men were consented, of whom 68% (551) completed genetic testing, and 8.7% (48 of 551) were found to carry a pathogenic or likely pathogenic variant in a germline DNA repair gene: CHEK2 (17), BRCA2 (15), ATM (6), NBN1 (3), BRCA1 (2), PALB2 (2), PMS2 (2), and MSH6 (1). Participants were more likely to complete the testing process if they were non-Hispanic White, married, highly educated, or from a higher-income bracket. CONCLUSION Here, we show the feasibility of delivering germline (inherited) genetic testing by a voluntary, patient-driven, Internet-based platform to men with mPC. Preliminary results show rates of germline DNA repair mutations, consistent with other cohorts. Although feasible for some, reduced steps for participation, more dedicated diverse outreach and participant support, and identification and addressing of additional barriers is needed to ensure equitable access and optimization.

Subjects

Subjects :
Cancer Research
Oncology

Details

ISSN :
24734284
Database :
OpenAIRE
Journal :
JCO Precision Oncology
Accession number :
edsair.doi...........35db7251bd88e8b079cb1a19ca9ae42e
Full Text :
https://doi.org/10.1200/po.22.00104